Trial Profile
Special Drug Use Investigation of EYLEA for AMD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Bayer
- 24 Jun 2019 Status changed from active, no longer recruiting to completed.
- 22 Mar 2019 Planned primary completion date changed from 28 Feb 2019 to 1 Apr 2019.
- 22 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 28 Feb 2019.